Document Detail


Relationship between Changes in Plasma Adiponectin Concentration and Insulin Sensitivity after Niacin Therapy.
MedLine Citation:
PMID:  22969777     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Niaspan® (extended-release niacin) is a nicotinic acid formulation used to treat dyslipidemia in obese subjects. Niaspan binds to the GPR109A receptor in adipose tissue and stimulates adiponectin secretion, which should improve insulin sensitivity. However, Niaspan therapy often causes insulin resistance. The purpose of this study was to evaluate whether Niaspan-induced changes in plasma adiponectin concentration are associated with a blunting of Niaspan's adverse effect on insulin action in obese subjects with non-alcoholic fatty liver disease (NAFLD). METHODS: A hyperinsulinemic-euglycemic clamp procedure was used to assess muscle insulin sensitivity before and after 16 weeks of Niaspan therapy in 9 obese subjects with NAFLD [age 43 ± 5 years; BMI 35.1 ± 1.3 (means ± SEM)]. RESULTS: Niaspan therapy did not affect body weight (99.1 ± 4.2 vs. 100 ± 4.4 kg) or percent body fat (37.8 ± 2.5 vs. 37.0 ± 2.5%). However, Niaspan therapy caused a 22% reduction in insulin-mediated glucose disposal (p < 0.05). The deterioration in glucose disposal was inversely correlated with the Niaspan-induced increase in plasma adiponectin concentration (r = 0.67, p = 0.05). CONCLUSIONS: These results demonstrate that Niaspan causes skeletal muscle insulin resistance, independent of changes in body weight or body fat, and the Niaspan-induced increase in plasma adiponectin concentration might partially ameliorate Niaspan's adverse effect on insulin action in obese subjects with NAFLD.
Authors:
Gemma Fraterrigo; Elisa Fabbrini; Bettina Mittendorfer; Stephen O'Rahilly; Philipp E Scherer; Bruce W Patterson; Samuel Klein
Related Documents :
7593897 - Immediate metabolic effects of different nutritional regimens in critically ill medical...
25137027 - Role of melanocortin signaling in neuroendocrine and metabolic actions of leptin in mal...
3764967 - Effect of pharmacological doses of 3-0-methyl-d-glucose and 2-deoxy-d-glucose on rat br...
23246247 - Insulin sparing action of adenovirus 36 and its e4orf1 protein.
2264327 - Comparison of plasma viscosity and fibrinogen concentration in african insulin-dependen...
21337987 - Evidence-based practice protocol to improve glucose control in individuals with type 2 ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-7-18
Journal Detail:
Title:  Cardiorenal medicine     Volume:  2     ISSN:  1664-5502     ISO Abbreviation:  Cardiorenal Med     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-9-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101554863     Medline TA:  Cardiorenal Med     Country:  -    
Other Details:
Languages:  ENG     Pagination:  211-217     Citation Subset:  -    
Affiliation:
Division of Geriatrics and Nutritional Science, Center for Human Nutrition, Washington University School of Medicine, St. Louis, Mo., Tex., USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Loss of Estrogen Receptor ? Signaling Leads to Insulin Resistance and Obesity in Young and Adult Fem...
Next Document:  Silent Ischemic Heart Disease in a Patient with Necrotizing Glomerulonephritis due to Wegener's Gran...